FindTrial
Sign In

Study on the efficacy, safety, survival rate and prognostic factors of neoadjuvant immunotherapy combined with chemotherapy in resectable locally advanced esophageal squamous cell carcinoma: A real-world retrospective study

Study on the efficacy, safety, survival rate and prognostic factors of neoadjuvant immunotherapy combined with chemotherapy in resectable locally advanced esophageal squamous cell carcinoma: A real-world retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114288
Enrollment
Unknown
Registered
2025-12-10
Start date
2025-03-25
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resectable locally advanced esophageal squamous cell carcinoma

Interventions

Observation group of resectable locally advanced esophageal squamous cell carcinoma:None

Sponsors

Shanxi Provincel Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients with locally advanced esophageal squamous cell carcinoma who have undergone R0 resection; 2. Age: 18-75 years old; 3.ECOG: 0-1 At least two cycles of neoadjuvant chemotherapy combined with immunotherapy should be administered before the operation.

Exclusion criteria

Exclusion criteria: 1. Pathological non-squamous cell carcinoma; 2. Preoperative neoadjuvant therapy < 2 cycles; 3.There is a history of other malignant tumors within 5 years.

Design outcomes

Primary

MeasureTime frame
Pathological complete response rate (pCR);Pathological significant response rate (MPR);R0 resection rate;—

Countries

China

Contacts

Public ContactWenhui Yang

Shanxi Provincel Cancer Hospital

yangwenhui-10012@163.com+86 15835133400

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026